Trends in Parasitology
ForumAntibody Therapy Goes to Insects: Monoclonal Antibodies Can Block Plasmodium Transmission to Mosquitoes
Section snippets
Antibodies Can Be Allies in the Fight against Malaria Transmission
Recent progress in malaria control has stalled, highlighting the need for new approaches and strategies to control and eliminate this disease. The antibody response to malaria has been extensively characterized [1], and potent neutralizing antibodies against Plasmodium falciparum can be important complementary tools to prevent and treat infection. The P. falciparum genome encodes over 5000 known or hypothetical proteins; those targeted by antibodies are often highly polymorphic, and
Pfs48/45
The GPI-anchored protein Pfs48/45 forms a complex with peripheral membrane protein Pfs230 on the surface of gametes and is essential for male fertility. Antibodies against Pfs48/45 prevent ookinete formation and are complement-independent. While Pfs48/45-specific polyclonal antibodies from human subjects have been shown to block transmission in a standard membrane feeding assay (SMFA) [4], no human monoclonal antibodies (mAbs) against Pfs48/45 have been reported. Rat mAb 85RF45.1 targets a
Perspectives on Delivery of mAbs Targeting Sexual-stage Parasite Antigens
The idea of therapeutic antibodies is not new to the malaria field. Seminal studies showed that intraperitoneal administration of sera from animals with chronic infection can reduce both parasite burden and clinical symptoms in infected Rhesus monkeys [12]. Further, passive transfer of IgG purified from semi-immune African adults cleared parasitemia in children with malaria [13]. Antibody-based therapy for malaria is being revisited in the era of recombinant antibodies, and now includes
Author Contributions
C.H.C. and P.E.D. conceptualized the work. All authors wrote and revised the manuscript.
Acknowledgments
C.H.C., G.E.C., C.B.M., and P.E.D. are supported by the Intramural Research Program of the National Institute of Allergy and Infectious Diseases, National Institutes of Health. T.B. and M.M.J. are supported by the Netherlands Organization for Scientific Research (Vidi fellowship NWO project numbers 016.158.306 and 192.061). J. Patrick Gorres edited the manuscript. G.E.C. is thankful to Adeline E. Williams for the revision in the Pfs47 section.
References (15)
Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum
Mol. Biochem. Parasitol.
(1989)Structural and immunological characterization of recombinant 6-cysteine domains of the Plasmodium falciparum sexual stage protein Pfs230
J. Biol. Chem.
(2016)Treatment of East African P. falciparum malaria with West African human gamma-globulin
Trans. R. Soc. Trop. Med. Hyg.
(1963)Transmission-blocking vaccines for malaria: time to talk about vaccine introduction
Trends Parasitol.
(2019)Safety and immunogenicity of Pfs25H-EPA/Alhydrogel, a transmission-blocking vaccine against Plasmodium falciparum: a randomised, double-blind, comparator-controlled, dose-escalation study in healthy Malian adults
Lancet Infect. Dis.
(2018)Immunity to malaria: more questions than answers
Nat. Immunol.
(2008)Variations in the quality of malaria-specific antibodies with transmission intensity in a seasonal malaria transmission area of Northern Ghana
PLoS One
(2017)
Cited by (7)
Monoclonal Antibodies for Protozoan Infections: A Future Reality or a Utopic Idea?
2021, Frontiers in MedicineMalaria-Resistant Mosquitoes (Diptera: Culicidae); the Principle is Proven, but Will the Effectors Be Effective?
2021, Journal of Medical Entomology